PMZ725
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $119,136 | 51 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $119,136 | 51 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A THREE MONTH MULTICENTER DOUBLE MASKED STUDY OF THE EFFICACY AND SAFETY OF TRAVOPROST 0015 TIMOLOL 01 VISCOUS SOLUTION COMPARED TO TRAVOPROST 0015 VISCOUS SOLUTION AND TIMOLOL 01 VISCOUS SOLUTION IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION | Novartis Pharmaceuticals Corporation | $76,595 | 0 |
| A THREE-MONTH, MULTICENTER, DOUBLE-MASKED STUDY OF THE EFFICACY AND SAFETY OF TRAVOPROST 0.0015%/TIMOLOL 0.1% VISCOUS SOLUTION, COMPARED TO TRAVOPROST 0.004% AND TIMOLOL 0.5% DOSED CONCOMITANTLY, IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION | Novartis Pharmaceuticals Corporation | $40,791 | 0 |
| A THREE MONTH MULTICENTER DOUBLE MASKED STUDY OF THE EFFICACY AND SAFETY OF TRAVOPROST 0015 TIMOLOL 01 VISCOUS SOLUTION COMPARED TO TRAVOPROST 0015 VISCOUS SOLUTION AND TIMOLOL 01 VISCOUS SOLUTION IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION | NOVARTIS PHARMACEUTICALS CORPORATION | $1,750 | 0 |
Top Doctors Receiving Payments for PMZ725
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Rochester, NY | $119,136 | 51 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $119,136
- Total Doctors 0
- Transactions 51
About PMZ725
PMZ725 is a drug associated with $119,136 in payments to 0 healthcare providers, recorded across 51 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2018 to 2018. In 2018, $119,136 was paid across 51 transactions to 0 doctors.
The most common payment nature for PMZ725 is "Unspecified" ($119,136, 100.0% of total).
PMZ725 is associated with 3 research studies, including "A THREE MONTH MULTICENTER DOUBLE MASKED STUDY OF THE EFFICACY AND SAFETY OF TRAVOPROST 0015 TIMOLOL 01 VISCOUS SOLUTION COMPARED TO TRAVOPROST 0015 VISCOUS SOLUTION AND TIMOLOL 01 VISCOUS SOLUTION IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION" ($76,595).